Literature DB >> 32332014

Therapeutic Efficacy of Immune Stimulatory Thymidine Kinase and fms-like Tyrosine Kinase 3 Ligand (TK/Flt3L) Gene Therapy in a Mouse Model of High-Grade Brainstem Glioma.

Flor Mendez1, Padma Kadiyala1,2, Felipe J Nunez1,2, Stephen Carney1,2, Fernando M Nunez1,2, Jessica C Gauss1,2, Ramya Ravindran1,2, Sheeba Pawar1,2, Marta Edwards, Maria Belen Garcia-Fabiani1,2, Santiago Haase1,2, Pedro R Lowenstein1,2, Maria G Castro3,2.   

Abstract

PURPOSE: Diffuse intrinsic pontine glioma (DIPG) bears a dismal prognosis. A genetically engineered brainstem glioma model harboring the recurrent DIPG mutation, Activin A receptor type I (ACVR1)-G328V (mACVR1), was developed for testing an immune-stimulatory gene therapy. EXPERIMENTAL
DESIGN: We utilized the Sleeping Beauty transposase system to generate an endogenous mouse model of mACVR1 brainstem glioma. Histology was used to characterize and validate the model. We performed RNA-sequencing analysis on neurospheres harboring mACVR1. mACVR1 neurospheres were implanted into the pons of immune-competent mice to test the therapeutic efficacy and toxicity of immune-stimulatory gene therapy using adenoviruses expressing thymidine kinase (TK) and fms-like tyrosine kinase 3 ligand (Flt3L). mACVR1 neurospheres expressing the surrogate tumor antigen ovalbumin were generated to investigate whether TK/Flt3L treatment induces the recruitment of tumor antigen-specific T cells.
RESULTS: Histologic analysis of mACVR1 tumors indicates that they are localized in the brainstem and have increased downstream signaling of bone morphogenetic pathway as demonstrated by increased phospho-smad1/5 and Id1 levels. Transcriptome analysis of mACVR1 neurosphere identified an increase in the TGFβ signaling pathway and the regulation of cell differentiation. Adenoviral delivery of TK/Flt3L in mice bearing brainstem gliomas resulted in antitumor immunity, recruitment of antitumor-specific T cells, and increased median survival (MS).
CONCLUSIONS: This study provides insights into the phenotype and function of the tumor immune microenvironment in a mouse model of brainstem glioma harboring mACVR1. Immune-stimulatory gene therapy targeting the hosts' antitumor immune response inhibits tumor progression and increases MS of mice bearing mACVR1 tumors. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 32332014      PMCID: PMC7415674          DOI: 10.1158/1078-0432.CCR-19-3714

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  70 in total

Review 1.  Treatment of diffuse intrinsic brainstem gliomas: failed approaches and future strategies.

Authors:  James L Frazier; James Lee; Ulrich W Thomale; Joseph C Noggle; Kenneth J Cohen; George I Jallo
Journal:  J Neurosurg Pediatr       Date:  2009-04       Impact factor: 2.375

2.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

Review 3.  Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope?

Authors:  Kenneth J Cohen; Nada Jabado; Jacques Grill
Journal:  Neuro Oncol       Date:  2017-08-01       Impact factor: 12.300

4.  Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class.

Authors:  W Caleb Rutledge; Jun Kong; Jingjing Gao; David A Gutman; Lee A D Cooper; Christina Appin; Yuna Park; Lisa Scarpace; Tom Mikkelsen; Mark L Cohen; Kenneth D Aldape; Roger E McLendon; Norman L Lehman; C Ryan Miller; Matthew J Schniederjan; Cameron W Brennan; Joel H Saltz; Carlos S Moreno; Daniel J Brat
Journal:  Clin Cancer Res       Date:  2013-07-17       Impact factor: 12.531

5.  Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy.

Authors:  Nicole A P Lieberman; Kole DeGolier; Heather M Kovar; Amira Davis; Virginia Hoglund; Jeffrey Stevens; Conrad Winter; Gail Deutsch; Scott N Furlan; Nicholas A Vitanza; Sarah E S Leary; Courtney A Crane
Journal:  Neuro Oncol       Date:  2019-01-01       Impact factor: 12.300

6.  Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease.

Authors:  Sophie E M Veldhuijzen van Zanten; Joshua Baugh; Brooklyn Chaney; Dennis De Jongh; Esther Sanchez Aliaga; Frederik Barkhof; Johan Noltes; Ruben De Wolf; Jet Van Dijk; Antonio Cannarozzo; Carin M Damen-Korbijn; Jan A Lieverst; Niclas Colditz; Marion Hoffmann; Monika Warmuth-Metz; Brigitte Bison; David T W Jones; Dominik Sturm; Gerrit H Gielen; Chris Jones; Esther Hulleman; Raphael Calmon; David Castel; Pascale Varlet; Géraldine Giraud; Irene Slavc; Stefaan Van Gool; Sandra Jacobs; Filip Jadrijevic-Cvrlje; David Sumerauer; Karsten Nysom; Virve Pentikainen; Sanna-Maria Kivivuori; Pierre Leblond; Natasha Entz-Werle; Andre O von Bueren; Antonis Kattamis; Darren R Hargrave; Péter Hauser; Miklos Garami; Halldora K Thorarinsdottir; Jane Pears; Lorenza Gandola; Giedre Rutkauskiene; Geert O Janssens; Ingrid K Torsvik; Marta Perek-Polnik; Maria J Gil-da-Costa; Olga Zheludkova; Liudmila Shats; Ladislav Deak; Lidija Kitanovski; Ofelia Cruz; Andres Morales La Madrid; Stefan Holm; Nicolas Gerber; Rejin Kebudi; Richard Grundy; Enrique Lopez-Aguilar; Marta Zapata-Tarres; John Emmerik; Tim Hayden; Simon Bailey; Veronica Biassoni; Maura Massimino; Jacques Grill; William P Vandertop; Gertjan J L Kaspers; Maryam Fouladi; Christof M Kramm; Dannis G van Vuurden
Journal:  J Neurooncol       Date:  2017-01-21       Impact factor: 4.130

7.  Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity.

Authors:  Matthew R Schuelke; Phonphimon Wongthida; Jill Thompson; Timothy Kottke; Christopher B Driscoll; Amanda L Huff; Kevin G Shim; Matt Coffey; Jose Pulido; Laura Evgin; Richard G Vile
Journal:  J Immunother Cancer       Date:  2019-07-17       Impact factor: 13.751

8.  ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis.

Authors:  Christine M Hoeman; Francisco J Cordero; Guo Hu; Katie Misuraca; Megan M Romero; Herminio J Cardona; Javad Nazarian; Rintaro Hashizume; Roger McLendon; Paul Yu; Daniele Procissi; Samantha Gadd; Oren J Becher
Journal:  Nat Commun       Date:  2019-03-04       Impact factor: 14.919

9.  HMGB1 mediates endogenous TLR2 activation and brain tumor regression.

Authors:  James F Curtin; Naiyou Liu; Marianela Candolfi; Weidong Xiong; Hikmat Assi; Kader Yagiz; Matthew R Edwards; Kathrin S Michelsen; Kurt M Kroeger; Chunyan Liu; A K M Ghulam Muhammad; Mary C Clark; Moshe Arditi; Begonya Comin-Anduix; Antoni Ribas; Pedro R Lowenstein; Maria G Castro
Journal:  PLoS Med       Date:  2009-01-13       Impact factor: 11.069

10.  Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma.

Authors:  Kathryn R Taylor; Alan Mackay; Nathalène Truffaux; Yaron Butterfield; Olena Morozova; Cathy Philippe; David Castel; Catherine S Grasso; Maria Vinci; Diana Carvalho; Angel M Carcaboso; Carmen de Torres; Ofelia Cruz; Jaume Mora; Natacha Entz-Werle; Wendy J Ingram; Michelle Monje; Darren Hargrave; Alex N Bullock; Stéphanie Puget; Stephen Yip; Chris Jones; Jacques Grill
Journal:  Nat Genet       Date:  2014-04-06       Impact factor: 38.330

View more
  10 in total

Review 1.  Tumour immune landscape of paediatric high-grade gliomas.

Authors:  James L Ross; Jose Velazquez Vega; Ashley Plant; Tobey J MacDonald; Oren J Becher; Dolores Hambardzumyan
Journal:  Brain       Date:  2021-10-22       Impact factor: 13.501

2.  Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma.

Authors:  Michael I Chastkofsky; Katarzyna C Pituch; Hiroaki Katagi; Markella Zannikou; Liliana Ilut; Ting Xiao; Yu Han; Adam M Sonabend; David T Curiel; Erin R Bonner; Javad Nazarian; Craig M Horbinski; C David James; Amanda M Saratsis; Rintaro Hashizume; Maciej S Lesniak; Irina V Balyasnikova
Journal:  Clin Cancer Res       Date:  2020-12-03       Impact factor: 13.801

3.  Genetically Engineered Mouse Model of Brainstem High-Grade Glioma.

Authors:  Fernando M Nunez; Jessica C Gauss; Flor M Mendez; Santiago Haase; Pedro R Lowenstein; Maria G Castro
Journal:  STAR Protoc       Date:  2020-11-25

4.  Immune-stimulatory (TK/Flt3L) gene therapy opens the door to a promising new treatment strategy against brainstem gliomas.

Authors:  Syed M Faisal; Flor M Mendez; Fernando Nunez; Maria G Castro; Pedro R Lowenstein
Journal:  Oncotarget       Date:  2020-12-15

Review 5.  Current Approaches for Glioma Gene Therapy and Virotherapy.

Authors:  Kaushik Banerjee; Felipe J Núñez; Santiago Haase; Brandon L McClellan; Syed M Faisal; Stephen V Carney; Jin Yu; Mahmoud S Alghamri; Antonela S Asad; Alejandro J Nicola Candia; Maria Luisa Varela; Marianela Candolfi; Pedro R Lowenstein; Maria G Castro
Journal:  Front Mol Neurosci       Date:  2021-03-11       Impact factor: 5.639

Review 6.  Receptor tyrosine kinase (RTK) targeting in pediatric high-grade glioma and diffuse midline glioma: Pre-clinical models and precision medicine.

Authors:  Kallen Schwark; Dana Messinger; Jessica R Cummings; Joshua Bradin; Abed Kawakibi; Clarissa M Babila; Samantha Lyons; Sunjong Ji; Rodrigo T Cartaxo; Seongbae Kong; Evan Cantor; Carl Koschmann; Viveka Nand Yadav
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738

Review 7.  Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.

Authors:  Maria B Garcia-Fabiani; Santiago Haase; Andrea Comba; Stephen Carney; Brandon McClellan; Kaushik Banerjee; Mahmoud S Alghamri; Faisal Syed; Padma Kadiyala; Felipe J Nunez; Marianela Candolfi; Antonela Asad; Nazareno Gonzalez; Marisa E Aikins; Anna Schwendeman; James J Moon; Pedro R Lowenstein; Maria G Castro
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 5.738

Review 8.  Histone-Mutant Glioma: Molecular Mechanisms, Preclinical Models, and Implications for Therapy.

Authors:  Maya S Graham; Ingo K Mellinghoff
Journal:  Int J Mol Sci       Date:  2020-09-29       Impact factor: 5.923

Review 9.  Current Immunotherapeutic Approaches for Malignant Gliomas.

Authors:  Myung-Hoon Han; Choong Hyun Kim
Journal:  Brain Tumor Res Treat       Date:  2022-01

10.  Bioinformatics analysis of the prognostic value of NEK8 and its effects on immune cell infiltration in glioma.

Authors:  Meng Xiao; Chaoyang Du; Chuanbo Zhang; Xinzhong Zhang; Shaomin Li; Dainan Zhang; Wang Jia
Journal:  J Cell Mol Med       Date:  2021-08-10       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.